Guselkumab

In FUZION, TREMFYA 100 mg q8w combined remission rose from 28% at Week 24 to 35% at Week 48; 200 mg q4w rates remained stable and safety was consistent through one year.

Phase 3 GALAXI 2 and 3 Week 144 LTE data report high rates of clinical, corticosteroid‑free and endoscopic remission with two maintenance regimens; 74% remained on treatment at three years.

Phase 4 STAR trial: guselkumab improved BASDAI at Week 24, reduced ASDAS‑CRP and MRI sacroiliac inflammation in biologic‑naïve axial PsA; safety profile consistent.

Quarterly sales topped $25.3B; adjusted net earnings and EPS rose, free cash flow improved, and full-year revenue guidance was raised above $100B for the first time.

APEX Phase‑3b: in biologic‑naïve PsA patients, 24‑week results met ACR20 and significantly inhibited structural joint damage vs placebo; placebo switchers had 57% less radiographic progression to Week 48; safety unchanged.

TREMFYA® maintains clinical, endoscopic, and histologic outcomes in ulcerative colitis through 140 weeks, with high patient retention and no new safety concerns.

TREMFYA® gains EC approval for treating moderate to severe plaque psoriasis in children, marking the first IL-23 inhibitor for pediatric use.